ERC1671

Unassigned

New Medicines

Recurrent or progressive glioma

Information

Advanced therapy medicinal product (ATMP) - cell therapy
Epitopoietic Research Corporation
Epitopoietic Research Corporation

Development and Regulatory status

None
None
Phase II Clinical Trials
Yes
Yes

Category

ERC 1671 comprises allogeneic and autologous haptenised and irradiated cells and cell lysates that are derived from patients with glioma
Annual incidence of malignant glioma is 3-5 per 100,000 [1].
Recurrent or progressive glioma
Intradermal